First step towards predicting clinical immunogenicity of biologics using in vitro based readouts as animal trial alternatives
- 24 April 2026
- journal article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (6) , 104297
Abstract
No abstract availableKeywords
Funding Information
- State University of New York
- National Institute of Allergy and Infectious Diseases (R01 AI-169296)
- Departement Farmaceutische Wetenschappen, Universiteit Utrecht
- Center for Protein Therapeutics, University at Buffalo
- National Institutes of Health
This publication has 25 references indexed in Scilit:
- Residual DNA impurities in AAV vectors—nature and transcriptionMolecular Therapy - Methods & Clinical Development, 2025
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccinesSignal Transduction and Targeted Therapy, 2025
- A mechanistic marker-based screening tool to predict clinical immunogenicity of biologicsCommunications Medicine, 2023
- Methods for addressing host cell protein impurities in biopharmaceutical product developmentBiotechnology Journal, 2022
- Engineering the next generation of cell-based therapeuticsNature Reviews Drug Discovery, 2022
- Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cellsmAbs, 2021
- Lipid-Reduction Variability and Antidrug-Antibody Formation with BococizumabNew England Journal of Medicine, 2017
- Cytokine release assays: Current practices and future directionsCytokine, 2014
- Minimizing the immunogenicity of protein therapeuticsDrug Discovery Today, 2004
- Cytokine and Cytokine Receptor Pleiotropy and RedundancyJournal of Biological Chemistry, 2002